Which parameters predict the beneficial effect of GnRHa treatment on height in girls with central precocious puberty?

VURALLI KARAOĞLAN D., Gonc N. E., ÖZÖN Z. A., KANDEMİR N., ALİKAŞİFOĞLU A.

CLINICAL ENDOCRINOLOGY, vol.94, no.5, pp.804-810, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 94 Issue: 5
  • Publication Date: 2021
  • Doi Number: 10.1111/cen.14420
  • Journal Name: CLINICAL ENDOCRINOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, Gender Studies Database, MEDLINE
  • Page Numbers: pp.804-810
  • Keywords: body height, bone age measurement, central precocious puberty, child, gonadotropin&#8208, releasing hormone, idiopathic sexual precocity, leuprolide
  • Hacettepe University Affiliated: Yes

Abstract

Objective Data about GnRHa on adult height in girls with central precocious puberty (CPP) have shown variable results, ranging from improvement of growth prognosis to lack of any benefit. This study was designed to delineate the criteria to decide which girls with idiopathic CPP (iCPP) will have a height benefit from GnRHa treatment.